# Sanofi Completes $9.5B Acquisition of Blueprint Medicines

> ma · REPORTED · 2025-07-18

Sanofi completed its $9.5 billion acquisition of Blueprint Medicines on July 18, 2025, adding the FDA-approved systemic mastocytosis drug Ayvakit and a late-stage oncology and immunology pipeline anchored by elenestinib and BLU-808.

- Company: Sanofi
- Sector: oncology
- Primary source: https://dealforma.com/global-healthcare-and-life-sciences-ma-2025-review/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.